Treatment for Shock

Phase-Based Progress Estimates
Shock+1 More
Angiotensin II - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new treatment for distributive shock that may help people who have had a heart transplant or implantation of a left ventricular assist device.

Eligible Conditions
  • Shock
  • Distributive Shock

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 10 Secondary · Reporting Duration: 1 year

1 year
Hospital length of stay
Intensive care unit (ICU) length of stay
24 hours
Cumulative time spent with MAP < 70 mmHg
Fluid overload
Incidence of new tachyarrhythmia
Time to extubation
Total catecholamine dose
Units of blood transfused
30 days
30-day mortality
48 hours
Incidence of acute kidney injury
Incidence of stroke

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Non-Treatment Group

40 Total Participants · 2 Treatment Groups

Primary Treatment: Treatment · Has Placebo Group · Phase 4

ActiveComparator Group · 1 Intervention: Angiotensin II · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,432 Previous Clinical Trials
769,497 Total Patients Enrolled
La Jolla Pharmaceutical CompanyIndustry Sponsor
21 Previous Clinical Trials
2,626 Total Patients Enrolled
6 Trials studying Shock
506 Patients Enrolled for Shock
Choy Lewis, MDPrincipal InvestigatorNorthwestern University

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Shock that occurs within 48 hours after heart transplantation or VAD placement is called distributive shock
People who are 18 years of age or older can be patients.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: October 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.